Home LiteratureArticle Details
PMID: 17035317 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Journal of virology ·Vol. 80 ·No. 24 ·2006-12-00 ·Pages 12149-59

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS

Abstract

Previous studies have demonstrated that monoclonal antibodies (MAbs) against an epitope on the lateral surface of domain III (DIII) of the West Nile virus (WNV) envelope (E) strongly protect against infection in animals. Herein, we observed significantly less efficient neutralization by 89 MAbs that recognized domain I (DI) or II (DII) of WNV E protein. Moreover, in cells expressing Fc gamma receptors, many of the DI- and DII-specific MAbs enhanced infection over a broad range of concentrations. Using yeast surface display of E protein variants, we identified 25 E protein residues to be critical for recognition by DI- or DII-specific neutralizing MAbs. These residues cluster into six novel and one previously characterized epitope located on the lateral ridge of DI, the linker region between DI and DIII, the hinge interface between DI and DII, and the lateral ridge, central interface, dimer interface, and fusion loop of DII. Approximately 45% of DI-DII-specific MAbs showed reduced binding with mutations in the highly conserved fusion loop in DII: 85% of these (34 of 40) cross-reacted with the distantly related dengue virus (DENV). In contrast, MAbs that bound the other neutralizing epitopes in DI and DII showed no apparent cross-reactivity with DENV E protein. Surprisingly, several of the neutralizing epitopes were located in solvent-inaccessible positions in the context of the available pseudoatomic model of WNV. Nonetheless, DI and DII MAbs protect against WNV infection in mice, albeit with lower efficiency than DIII-specific neutralizing MAbs.

MeSH Terms
Animals Antibodies, Monoclonal/genetics,immunology Antibody Specificity/genetics,immunology Cell Line Epitope Mapping Epitopes/genetics Mice Mutation/genetics Neutralization Tests Protein Structure, Tertiary/genetics Receptors, IgG/immunology Viral Envelope Proteins/genetics,immunology West Nile virus/genetics,immunology Yeasts
Chemicals
Antibodies, Monoclonal Epitopes Receptors, IgG Viral Envelope Proteins
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Oliphant Theodore
Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave., Box 8051, Saint Louis, MO 63110, USA.
Nybakken Grant E
Engle Michael
Xu Qing
Nelson Christopher A
Sukupolvi-Petty Soila
Marri Anantha
Lachmi Bat-El
Olshevsky Udy
Fremont Daved H
Pierson Theodore C
Diamond Michael S
References (64)
64 references, click to expand
  1. Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages.
    Nature. 1981 Jan 15;289(5794):189-91 PMID: 7453820
  2. Crystal structure of the West Nile virus envelope glycoprotein.
    J Virol. 2006 Dec;80(23):11467-74 PMID: 16987985
  3. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    J Gen Virol. 1986 Feb;67 ( Pt 2):229-34 PMID: 3944585
  4. Characterization of neutralizing antibodies to West Nile virus.
    Virology. 2005 May 25;336(1):70-82 PMID: 15866072
  5. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.
    Nat Med. 2005 May;11(5):522-30 PMID: 15852016
  6. Complement activation is required for induction of a protective antibody response against West Nile virus infection.
    J Virol. 2005 Jun;79(12):7466-77 PMID: 15919902
  7. Structural basis of West Nile virus neutralization by a therapeutic antibody.
    Nature. 2005 Sep 29;437(7059):764-9 PMID: 16193056
  8. Neutralizing monoclonal antibodies against Russian strain of the West Nile virus.
    Viral Immunol. 2005;18(3):558-68 PMID: 16212535
  9. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.
    J Virol. 2005 Dec;79(23):14606-13 PMID: 16282460
  10. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.
    J Virol. 2006 Feb;80(3):1290-301 PMID: 16415006
  11. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms.
    J Virol. 2006 Feb;80(3):1340-51 PMID: 16415011
  12. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.
    Virology. 2006 Mar 1;346(1):53-65 PMID: 16325883
  13. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection.
    Am J Trop Med Hyg. 1987 Mar;36(2):427-34 PMID: 3826503
  14. Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report.
    Arch Virol. 1987;93(3-4):295-301 PMID: 3827600
  15. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies.
    J Immunol. 1988 Nov 15;141(10):3606-10 PMID: 2460542
  16. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.
    Am J Trop Med Hyg. 1989 Apr;40(4):444-51 PMID: 2712199
  17. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection.
    Am J Trop Med Hyg. 1989 Nov;41(5):576-80 PMID: 2817214
  18. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection.
    J Immunol. 1990 Apr 15;144(8):3183-6 PMID: 2139079
  19. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever.
    Am J Trop Med Hyg. 1991 May;44(5):481-93 PMID: 2063952
  20. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein.
    Virology. 1992 Dec;191(2):921-31 PMID: 1280384
  21. Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
    J Gen Virol. 1993 May;74 ( Pt 5):839-44 PMID: 8492089
  22. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM.
    Virology. 1994 Jan;198(1):109-17 PMID: 8259646
  23. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2.
    Virology. 1994 Aug 1;202(2):885-90 PMID: 7518164
  24. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.
    Nature. 1995 May 25;375(6529):291-8 PMID: 7753193
  25. Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody.
    Virus Res. 1996 Aug;43(2):125-36 PMID: 8864202
  26. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
    Virology. 1998 Jul 5;246(2):317-28 PMID: 9657950
  27. New mouse model for dengue virus vaccine testing.
    J Virol. 1999 Jan;73(1):783-6 PMID: 9847388
  28. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses.
    J Virol. 2004 Dec;78(23):12910-8 PMID: 15542643
  29. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein.
    J Virol. 2004 Dec;78(23):12919-28 PMID: 15542644
  30. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes.
    J Virol. 2004 Dec;78(24):13975-86 PMID: 15564505
  31. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells.
    J Biol Chem. 2004 Dec 24;279(52):54533-41 PMID: 15475343
  32. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein.
    J Virol. 2005 Jan;79(2):1223-31 PMID: 15613349
  33. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.
    J Gen Virol. 2005 Feb;86(Pt 2):405-12 PMID: 15659760
  34. The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain.
    J Virol. 1999 Dec;73(12):9879-90 PMID: 10559300
  35. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.
    J Virol. 2000 Jun;74(11):4957-66 PMID: 10799569
  36. Human Dengue antibodies against structural and nonstructural proteins.
    Clin Diagn Lab Immunol. 2000 Sep;7(5):856-7 PMID: 10973471
  37. Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies.
    Virology. 2001 Jan 20;279(2):447-58 PMID: 11162801
  38. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.
    J Virol. 2001 Apr;75(8):4002-7 PMID: 11264392
  39. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.
    J Virol. 2001 May;75(9):4268-75 PMID: 11287576
  40. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.
    J Virol. 2001 Aug;75(16):7769-73 PMID: 11462053
  41. Partial genetic characterization of West Nile virus strains, New York State, 2000.
    Emerg Infect Dis. 2001 Jul-Aug;7(4):650-3 PMID: 11585527
  42. Antibody prophylaxis and therapy for flavivirus encephalitis infections.
    Ann N Y Acad Sci. 2001 Dec;951:286-97 PMID: 11797785
  43. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.
    Cell. 2002 Mar 8;108(5):717-25 PMID: 11893341
  44. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.
    J Virol. 2002 Dec;76(24):13097-100 PMID: 12438639
  45. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.
    J Virol. 2003 Feb;77(4):2578-86 PMID: 12551996
  46. A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites.
    J Virol. 2003 Feb;77(4):2600-6 PMID: 12551998
  47. A ligand-binding pocket in the dengue virus envelope glycoprotein.
    Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6986-91 PMID: 12759475
  48. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice.
    J Infect Dis. 2003 Jul 1;188(1):5-12 PMID: 12825165
  49. Structure of West Nile virus.
    Science. 2003 Oct 10;302(5643):248 PMID: 14551429
  50. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.
    J Virol. 2003 Dec;77(24):12941-9 PMID: 14645550
  51. A critical role for induced IgM in the protection against West Nile virus infection.
    J Exp Med. 2003 Dec 15;198(12):1853-62 PMID: 14662909
  52. Structure of the dengue virus envelope protein after membrane fusion.
    Nature. 2004 Jan 22;427(6972):313-9 PMID: 14737159
  53. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation.
    EMBO J. 2004 Feb 25;23(4):728-38 PMID: 14963486
  54. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.
    J Mol Biol. 2004 Sep 10;342(2):539-50 PMID: 15327953
  55. Conformational changes of the flavivirus E glycoprotein.
    Structure. 2004 Sep;12(9):1607-18 PMID: 15341726
  56. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines.
    Nature. 1979 Nov 29;282(5738):509-11 PMID: 503230
  57. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.
    J Infect Dis. 1979 Oct;140(4):527-33 PMID: 117061
  58. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection.
    J Immunol. 2006 Mar 1;176(5):2825-32 PMID: 16493039
  59. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.
    J Virol. 2006 Jul;80(14):6982-92 PMID: 16809304
  60. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody.
    Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12400-4 PMID: 16895988
  61. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.
    J Virol. 2006 Oct;80(19):9349-60 PMID: 16973541
  62. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.
    J Virol. 2006 Oct;80(19):9557-68 PMID: 16973559
  63. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.
    J Infect Dis. 2006 Nov 1;194(9):1300-8 PMID: 17041857
  64. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies.
    J Immunol. 1984 Mar;132(3):1533-7 PMID: 6198396
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2006-12-00
Epub
2006-00-11
Pages
12149-59
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1676294
Subset
IM
Grants
NIAID NIH HHS · U01 AI061373 · United States
NIAID NIH HHS · U54 AI057160 · United States
NIAID NIH HHS · AI061373 · United States
Intramural NIH HHS · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com